Exact Sciences' Cologuard Wins Prestigious Prix Galien Award for Best Medical Technology Product
10/28/2016
MADISON, Wis., Oct. 28, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that Cologuard, the first and only FDA-approved noninvasive, stool DNA-based colorectal cancer screening test, has won the 2016 10th Annual Prix Galien USA Award for best medical technology product. Awarded by the Galien Foundation, the Prix Galien USA awards are among the nation's highest honors recognizing biomedical and technology product achievement associated with improving the human condition.
"It's an extraordinary honor for Cologuard and the Exact Sciences team to be recognized in such a distinguished forum," said Graham Lidgard, Ph.D., chief science officer of Exact Sciences. "This Prix Galien award highlights not only the breakthrough science behind Cologuard, but also the unrivaled team that worked to develop and bring to market an innovation with the potential to make a significant impact in eradicating colorectal cancer. We are humbled and thankful to be counted among the companies honored by the Galien Foundation."
Awarded in more than a dozen countries, the Prix Galien awards recognize the best in biomedical research and development. Nominees for the Prix Galien USA awards represent the most innovative biopharma and medical technologies addressing public health priorities and are evaluated by a prestigious committee comprised of nine renowned leaders from the biomedical industry and academia, including four Nobel Laureates.
The awards were presented at the Prix Galien USA Awards Ceremony, which took place on Oct. 27 at the American Museum of Natural History in New York.
About the Galien Foundation
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.
The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.
http://investor.exactsciences.com/investor-re...fault.aspx
10/28/2016
MADISON, Wis., Oct. 28, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that Cologuard, the first and only FDA-approved noninvasive, stool DNA-based colorectal cancer screening test, has won the 2016 10th Annual Prix Galien USA Award for best medical technology product. Awarded by the Galien Foundation, the Prix Galien USA awards are among the nation's highest honors recognizing biomedical and technology product achievement associated with improving the human condition.
"It's an extraordinary honor for Cologuard and the Exact Sciences team to be recognized in such a distinguished forum," said Graham Lidgard, Ph.D., chief science officer of Exact Sciences. "This Prix Galien award highlights not only the breakthrough science behind Cologuard, but also the unrivaled team that worked to develop and bring to market an innovation with the potential to make a significant impact in eradicating colorectal cancer. We are humbled and thankful to be counted among the companies honored by the Galien Foundation."
Awarded in more than a dozen countries, the Prix Galien awards recognize the best in biomedical research and development. Nominees for the Prix Galien USA awards represent the most innovative biopharma and medical technologies addressing public health priorities and are evaluated by a prestigious committee comprised of nine renowned leaders from the biomedical industry and academia, including four Nobel Laureates.
The awards were presented at the Prix Galien USA Awards Ceremony, which took place on Oct. 27 at the American Museum of Natural History in New York.
About the Galien Foundation
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.
The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.
http://investor.exactsciences.com/investor-re...fault.aspx
